On March 20, 2017 Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, reported that it will present interim data from its ongoing Phase 1/1b study of CPI-444 as a single agent and in combination with Genentech’s Tecentriq (atezolizumab) in an oral plenary session at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2017, which is taking place April 1-5 in Washington, D.C (Press release, Corvus Pharmaceuticals, MAR 20, 2017, View Source [SID1234518211]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company will also present preclinical and clinical data on CPI-444, as well as preclinical data on its investigational humanized monoclonal anti-CD73 antibody, in poster presentations. In a separate invited oral presentation, CPI-444 will be featured as a novel oral checkpoint inhibitor of adenosine mediated suppression of tumor immunity. The following are details for the six oral and poster presentations. The abstract for the oral plenary session will be available on the AACR (Free AACR Whitepaper) website on March 31 at 4:30 p.m. ET.

ORAL PRESENTATIONS

ABSTRACT #: CT119
TITLE: CPI-444, an oral adenosine A2a receptor (A2AR) antagonist, demonstrates clinical activity in patients with advanced solid tumors
PRESENTER: Leisha Emens, M.D., Ph.D., associate professor of oncology, John Hopkins Sidney Kimmel Comprehensive Cancer Center
SESSION TYPE: Oral Plenary
PRESENTATION DATE AND TIME: Tuesday, April 4, 10:30 a.m.-12:45 p.m. ET
LOCATION: Ballroom C, Level 3, Washington Convention Center

TITLE: CPI-444 – A Novel Oral Checkpoint Inhibitor of Adenosine Mediated Suppression of Tumor Immunity
PRESENTER: Ian McCaffery, Ph.D., Corvus Pharmaceuticals
SESSION TYPE: Invited Oral
PRESENTATION DATE AND TIME: Saturday, April 1, 3:15-5:15 p.m. ET
LOCATION: Ballroom A-B, Level 3, Washington Convention Center

POSTER PRESENTATIONS

ABSTRACT #: 5593/POSTER #: 25
TITLE: Inhibition of A2AR induces anti-tumor immunity alone and in combination with anti-PD-L1 in preclinical and clinical studies
PRESENTER: Stephen Willingham, Ph.D., Corvus Pharmaceuticals
PRESENTATION DATE AND TIME: Wednesday, April 5, 8:00 a.m-12:00 p.m. ET
LOCATION: Convention Center, Halls A-C, Poster Section 24

ABSTRACT #: 5598/POSTER #: 30
TITLE: Adenosine signaling through A2AR limits the efficacy of anti-CTLA4 and chemotherapy in preclinical models
PRESENTER: Po Y. Ho, Corvus Pharmaceuticals
PRESENTATION DATE AND TIME: Wednesday, April 5, 8:00 a.m-12:00 p.m. ET
LOCATION: Convention Center, Halls A-C, Poster Section 24

ABSTRACT #: 5579/POSTER #: 11
TITLE: Strategic inhibition of adenosine A2A receptor (A2AR) by CPI-444 improves CD8+:Treg ratios and enhances T-cell killing of a HER-2/neu expressing murine tumor
PRESENTER: Blake A. Scott, Johns Hopkins University School of Medicine
PRESENTATION DATE AND TIME: Wednesday, April 5, 8:00 a.m-12:00 p.m. ET
LOCATION: Convention Center, Halls A-C, Poster Section 24

ABSTRACT #: 5577/POSTER #: 9
TITLE: A novel CD73-blocking antibody reduces production of immunosuppressive adenosine and restores T-cell function
PRESENTING AUTHOR: Emily Piccione, Ph.D., Corvus Pharmaceuticals
PRESENTATION DATE AND TIME: Wednesday, April 5, 8:00 a.m.-12:00 p.m. ET
LOCATION: Convention Center, Halls A-C, Poster Section 24